Key findings

To reduce the risk for postpartum relapse in pregnant women with active multiple sclerosis, a strategy of starting or restarting disease-modifying therapy (DMT) with natalizumab or fingolimod within 6 weeks of delivery appears to be optimal. This was among the key findings of a German study reported in ...